Quick Answer
Autolus Therapeutics plc reported Operating Income Loss of -$270.54 million for the year ending 2025.
- Autolus Therapeutics plc showed a decrease of -12.1% in Operating Income Loss from 2024 to 2025.
- This data is from Autolus Therapeutics plc's annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2018: -$25.01 million | Q1 2022: -$36.19 million | Q2 2022: -$39.06 million | Q3 2022: -$37.35 million | Q1 2023: -$39.15 million | Q2 2023: -$44.38 million | Q3 2023: -$42.91 million | Q1 2024: -$38.76 million | Q2 2024: -$58.93 million | Q3 2024: -$67.88 million | Q1 2025: -$65.24 million | Q2 2025: -$61.22 million | Q3 2025: -$71.62 million.
- Over the full 9 years of available data (2017 to 2025), Autolus Therapeutics plc's Operating Income Loss has declined by 1,055.3%.
- Historical annual values: Fiscal year 2025: -$270.54 million | Fiscal year 2024: -$241.43 million | Fiscal year 2023: -$179.70 million | Fiscal year 2022: -$143.41 million | Fiscal year 2021: -$141.05 million | Fiscal year 2020: -$168.15 million | Fiscal year 2019: -$146.06 million | Fiscal year 2018: -$57.53 million | Fiscal year 2017: -$23.42 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: